Literature DB >> 35581444

The association between platelet-lymphocyte ratio and the risk of all-cause mortality in chronic kidney disease: a systematic review and meta-analysis.

Wenyuan Gan1, Qingyu Guan1,2, Xiaosong Hu1, Xingruo Zeng1, Danni Shao1, Li Xu1, Wei Xiao1, Huihui Mao1, Wenli Chen3.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) patients have high levels of inflammatory mediators. These inflammatory mediators contribute to the increased risk of cardiovascular events and all-cause mortality. Platelet-lymphocyte ratio (PLR) has recently been recognized as a novel inflammatory marker and has been shown to be associated with the prognosis in CKD patients. However, the quality of these studies varies and their results are controversial. The purpose of this meta-analysis was to investigate the relationship between PLR and all-cause mortality in CKD patients.
METHODS: A systematic literature search of PubMed, EMBASE, CENTRAL and ISI Web of Science was conducted. The databases were searched from their inception dates up to the latest issue (31 October 2021). Two reviewers independently searched the databases and screened studies. Data were extracted using a standardized collection form. Meta-analysis was performed to compare PLR values between CKD and non-CKD patients, and to investigate the association between PLR and all-cause mortality in CKD patients. This meta-analysis is reported in adherence to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
RESULTS: A total of 11 studies involving 4244 participants were selected. The pooled data indicated that PLR values were significantly higher in CKD patients than non-CKD controls (weighted mean difference = 21.6, 95% CI 17.39-25.81, p < 0.01), and PLR is associated with an increased risk of all-cause mortality in CKD patients (hazard ratio = 2.49, 95% CI 1.78-3.49, p < 0.01).
CONCLUSIONS: Patients with CKD have higher PLR values compared to non-CKD patients. Meanwhile, PLR values were highly associated with all-cause mortality in CKD patients. PLR is a valid predictor as a clinically accessible indicator for patients with CKD.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  All-cause mortality; Chronic kidney disease; Meta-analysis; Platelet-lymphocyte ratio

Mesh:

Substances:

Year:  2022        PMID: 35581444     DOI: 10.1007/s11255-022-03234-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  33 in total

Review 1.  A perspective on chronic kidney disease progression.

Authors:  Jianyong Zhong; Hai-Chun Yang; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-14

2.  The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis.

Authors:  Yiting Tang; Fangfang Zhang; Ling Huang; Qiongjing Yuan; Jiao Qin; Bingxin Li; Nasui Wang; Yanyun Xie; Linghao Wang; Wei Wang; Kevin Kwan; Zhangzhe Peng; Gaoyun Hu; Jing Li; Lijian Tao
Journal:  Am J Med Sci       Date:  2015-09       Impact factor: 2.378

3.  Prevalence of chronic kidney disease in China: a cross-sectional survey.

Authors:  Luxia Zhang; Fang Wang; Li Wang; Wenke Wang; Bicheng Liu; Jian Liu; Menghua Chen; Qiang He; Yunhua Liao; Xueqing Yu; Nan Chen; Jian-e Zhang; Zhao Hu; Fuyou Liu; Daqing Hong; Lijie Ma; Hong Liu; Xiaoling Zhou; Jianghua Chen; Ling Pan; Wei Chen; Weiming Wang; Xiaomei Li; Haiyan Wang
Journal:  Lancet       Date:  2012-03-03       Impact factor: 79.321

4.  Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease.

Authors:  Marian Goicoechea; Borja Quiroga; Soledad García de Vinuesa; Ursula Verdalles; Javier Reque; Nayara Panizo; David Arroyo; Alba Santos; Nicolás Macías; José Luño
Journal:  Ren Fail       Date:  2012-06-29       Impact factor: 2.606

Review 5.  Chronic Kidney Disease Diagnosis and Management: A Review.

Authors:  Teresa K Chen; Daphne H Knicely; Morgan E Grams
Journal:  JAMA       Date:  2019-10-01       Impact factor: 56.272

6.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

Review 7.  Oxalate, inflammasome, and progression of kidney disease.

Authors:  Theresa Ermer; Kai-Uwe Eckardt; Peter S Aronson; Felix Knauf
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 8.  Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.

Authors:  Mark J Sarnak; Kerstin Amann; Sripal Bangalore; João L Cavalcante; David M Charytan; Jonathan C Craig; John S Gill; Mark A Hlatky; Alan G Jardine; Ulf Landmesser; L Kristin Newby; Charles A Herzog; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2019-10-08       Impact factor: 24.094

Review 9.  Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index.

Authors:  David Walzik; Niklas Joisten; Jonas Zacher; Philipp Zimmer
Journal:  Eur J Appl Physiol       Date:  2021-03-31       Impact factor: 3.078

10.  mRNA Interferase Bacillus cereus BC0266 Shows MazF-Like Characteristics Through Structural and Functional Study.

Authors:  Sung-Min Kang; Ji Sung Koo; Chang-Min Kim; Do-Hee Kim; Bong-Jin Lee
Journal:  Toxins (Basel)       Date:  2020-06-08       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.